Entrar/Registro  
HOME SPANISH
 
Revista Médica del Instituto Mexicano del Seguro Social
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2016, Issue S3


Martínez-Acosta JE, Olguín-Cruces VA
Association of ovarian tumors with CA-125
Rev Med Inst Mex Seguro Soc 2016; 54 (S3)

Language: Español
References: 24
Page: 230-237
PDF: 287.32 Kb.


Full text




ABSTRACT

Background: The tumor marker CA-125 is the most widely used serum marker for ovarian cancer screening. The aim of this paper was to establish the association between histopathologic result of ovarian tumors with serologic CA-125 and utility for the diagnosis of ovarian tumors at a Ginecoobstetric hospital.
Methods: An observational, retrospective, descriptive and longitudinal study, from September 1st 2010 to February 28 2013. All patients with histopathologic report ovarian tumor and CA-125 was selected to analyze the association of ovarian tumors with their histological type, biological behavior, range positivity of CA-125 and its relationship to the pre and postmenopausal state.
Results: Of 1213 patients, 334 were included. Utility of CA-125 in postmenopausal reported positive predictive value of 67.5%, with sensitivity (72%), specificity (82.6%) and negative predictive value (86.1%), both with p = 0.001, mainly in the epithelial origin. In premenopausal a low positive predictive value was reported.
Conclusions: The CA-125 is useful for screening for ovarian cancer in postmenopausal women, mainly for epithelial origin.


Key words: Antigens neoplas, Ovarian diseases, Ovarian neoplasms.


REFERENCIAS

  1. Morales VF, Santillán GA. Antígeno sérico CA-125 en cáncer epitelial de ovario. Cancerología 2; Suplemento 1 (2007): s21-s25.

  2. Muto MG. Approach to the patient with an adnexal mass. UpToDate Topic 3207 Version 17.0. Ene 30, 2013.

  3. Vivien W. Chen, Bernardo Ruiz, Jeffrey L. Killeen, Timothy R. Cote, Xiao Cheng Wu, Catherine N. Correa. Pathology and Classification of Ovarian Tumors. CANCER Supplement May 15, 2003 / Volume 97 / Number 10.

  4. Alexandre J, Brown C, Coeffic D, et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer (2012) 106, 633-637.

  5. Varughese E, Kondalsamy CS, Obermair A. The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study. Journal of Ovarian Research 2012, 5:11.

  6. Carlson KJ. Screening for ovarian cancer. UpToDate Topic 7563 Version 25.0. Feb 7, 2013.

  7. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA-125 concentration: a prospective cohort study. BMJ 1996; 313:1355.

  8. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA-125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42:677.

  9. Einhorn N, Sjövall K, Knapp RC, et al. Prospective evaluation of serum CA-125 levels for early detection of ovarian cancer. Obstet Gynecol 1992; 80:14.

  10. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA-125 measurement and ultrasonography. BMJ 1993; 306:1030.

  11. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:273S.

  12. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630.

  13. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113:775.

  14. Atención del Climaterio y Menopausia, México: Secretaría de Salud 2009.

  15. Committee of Gynecologic Practice. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Committee Opinion. No. 477, march 2011.

  16. Carlson KJ. Screening for ovarian cancer. UpToDate Topic 7563 Version 25.0. Feb 7, 2013.

  17. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42:677.

  18. Einhorn N, Sjövall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992; 80:14.

  19. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306:1030.

  20. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor de course of epithelial ovarian cancer. N Engl J Med 1983;309: 883-7.

  21. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.

  22. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Bechuck A, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993;85:1748-51.

  23. Muto MG. Management of an adnexal mass. UpTo- Date Topic 83704 Version 3.0. Feb 26, 2013.

  24. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.






>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2016, Issue S3
 

· Journal Index 
· Links 






       
Copyright 2019